StockNews.com Initiates Coverage on Genocea Biosciences (NASDAQ:GNCA)

Research analysts at StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Genocea Biosciences Stock Performance

The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35. Genocea Biosciences has a 52 week low of $0.00 and a 52 week high of $0.00. The stock has a market cap of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61.

About Genocea Biosciences

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.